Evaluation of the Efficacy, Safety, and Tolerability of Sarizotan in Rett Syndrome With Respiratory Symptoms

Learn more about:
Related Clinical Trial
The Role of Dietary Calcium for the Treatment of Osteopenia in Girls With Rett Syndrome Measuring Impact of Computer Gaming on Arm Use in Rett Syndrome An Open-Label Study of Trofinetide for the Treatment of Girls Two to Five Years of Age Who Have Rett Syndrome Development of the ORCA Communication Measure for Rett Syndrome The Rett Syndrome Global Registry Open-Label Extension Study of Trofinetide for Rett Syndrome ASSESSING EMERALD AND MC10 BIOSTAMP nPOINT BIOSENSORS FOR RETT SYNDROME Predictors of Caregiver Adaptation to Pervasive Developmental Disorders A Study of the Effectiveness and Safety of Risperidone Versus Placebo in the Treatment of Children With Autistic Disorder and Other Pervasive Developmental Disorders (PDD) New Genes Involved in Molecular Etiology of Rett Syndrome Through DNA Microarray Comparative Genomic Hybridization An Open-label Extension Study of Cannabidiol Oral Solution (GWP42003-P, CBD-OS) in Patients With Rett Syndrome ANAVEX2-73 Study in Pediatric Patients With Rett Syndrome ANAVEX2-73 Study in Patients With Rett Syndrome Study of Cardiac and Paroxysmal Abnormalities in Rett Syndrome Nutritional Aspects of Rett Syndrome Sleep Abnormalities in Rare Genetic Disorders: AS, RTT, and PW Study of the Pathogenesis of Rett Syndrome Advanced Grandparental Age as a Risk Factor for Autism A Safety Study of NNZ-2566 in Pediatric Rett Syndrome Treatment of Mitochondrial Dysfunction in Rett Syndrome With Triheptanoin Biobanking of Rett Syndrome and Related Disorders Telehealth Support to Increase Physical Activity in Rett Syndrome Open-Label Extension Study of Trofinetide for the Treatment of Girls and Women With Rett Syndrome An Open Label, Exploratory Study to Investigate the Treatment Effect of Glatiramer Acetate on Girls Woth Rett Syndrome Natural History of Rett Syndrome & Related Disorders Independent Studies of Dextromethorphan and of Donepezil Hydrochloride for Rett Syndrome Study of ANAVEX2-73 in Patients With Rett Syndrome Trial of Dextromethorphan in Rett Syndrome Pharmacological Treatment of Rett Syndrome With Statins An Exploratory Trial of Ketamine for the Treatment of Rett Syndrome Analysis of the Glutathione Cycle in Children With Rett Syndrome Efficacy and Safety of Cannabidiol Oral Solution (GWP42003-P, CBD-OS) in Patients With Rett Syndrome ‘Uptime’ Participation Intervention in Girls and Women With Rett Syndrome Functional Abilities in Rett Syndrome Treatment of Rett Syndrome With rhIGF-1 (Mecasermin [rDNA]Injection) Placebo Controlled Trial of Dextromethorphan in Rett Syndrome Effects of Creatine Supplementation in Rett Syndrome Metabolic Evaluation of Nutrition in Rett Syndrome Treatment of Rett Syndrome With Recombinant Human IGF-1 A Study to Evaluate Ketamine for the Treatment of Rett Syndrome Evaluation of the Efficacy, Safety, and Tolerability of Sarizotan in Rett Syndrome With Respiratory Symptoms A Safety Study of NNZ-2566 in Patients With Rett Syndrome Genetic and Physical Characteristics of Rett Syndrome Study of Trofinetide for the Treatment of Girls and Women With Rett Syndrome (LAVENDER™) The Role of Family Functioning in Adaptation to Being a Caregiver of an Individual With Rett Syndrome A Pilot Study of an Antioxidant Cocktail vs. Placebo in the Treatment of Children and Adolescents With Rett Syndrome The Findings of MR Imaging in Rett Syndrome Phase 2 Study of EPI-743 for Treatment of Rett Syndrome Open Label Trial of Triheptanoin (UX007) in Treatment of Rett Syndrome. Pharmacological Treatment of Rett Syndrome With Glatiramer Acetate (Copaxone) Study to Assess Safety and Efficacy of Fingolimod in Children With Rett Syndrome Pilot Study of the Effects of the Desipramine on the Neurovegetative Parameters of the Child With Rett Syndrome Patients With RETT Syndrome Creatine Metabolism in Rett Syndrome

Brief Title

Evaluation of the Efficacy, Safety, and Tolerability of Sarizotan in Rett Syndrome With Respiratory Symptoms

Official Title

A Randomised, Double-Blind, Placebo-Controlled 6-month Study to Evaluate the Efficacy, Safety, and Tolerability of Sarizotan in Patients With Rett Syndrome With Respiratory Symptoms

Brief Summary

      This study evaluates the safety, tolerability and efficacy of Sarizotan in reducing
      respiratory abnormalities in Rett Syndrome in an initial double blind 24 week period followed
      by an open label treatment phase of up to 168 weeks (the latter for patients with no safety
      and tolerability issues).
    

Detailed Description

      This is a randomized, double-blind, placebo-controlled study designed to evaluate the safety,
      tolerability, and efficacy of multiple doses of sarizotan in patients with Rett syndrome with
      respiratory abnormalities. The study participants will be randomized to either sarizotan
      between 2 and 10 mg bid or placebo bid, based on age and weight criteria.

      All patients who have completed the final evaluations at Week 24 (Day 168) and have no safety
      or tolerability issues that would preclude continuing on the study medication and have been
      compliant with the trial requirements will have the option of continuing open-label treatment
      with Sarizotan for up to 168 weeks.
    

Study Phase

Phase 2/Phase 3

Study Type

Interventional


Primary Outcome

Reduction in Respiratory Abnormality in Patients With Rett Syndrome

Secondary Outcome

 Efficacy of Sarizotan Assessed by the Caregiver-rated Impression of Change

Condition

Rett Syndrome

Intervention

Sarizotan low dose

Study Arms / Comparison Groups

 Sarizotan low dose
Description:  2 mg or 5 mg bid based on age and weight criteria for 24 wks DB 2 mg bid (4 to <13 years; ≥13 years of age and weighing <25 kg 5 mg bid (≥13 years of age and weighing ≥25 kg)

Publications

* Includes publications given by the data provider as well as publications identified by National Clinical Trials Identifier (NCT ID) in Medline.

Recruitment Information


Recruitment Status

Drug

Estimated Enrollment

129

Start Date

October 26, 2016

Completion Date

May 4, 2020

Primary Completion Date

August 6, 2019

Eligibility Criteria

        Inclusion Criteria:

          -  Body weight ≥ 10 kg

          -  Age ≥ 4 years

          -  Diagnosis of Rett syndrome based on consensus clinical criteria and patients with
             MECP2 duplications will not be eligible.

          -  Has at least 10 episodes of breathing dysrhythmia, defined by episodes ≥10 seconds of
             breath holding (apnea), per hour during cardiorespiratory monitoring

          -  Ability to take study medication provided either as capsules or combined with
             food/drink.

          -  Patient is cooperative, willing to complete all aspects of the study, and capable of
             doing so with assistance of a caregiver.

        Exclusion Criteria:

          -  Meets any of the diagnostic exclusion criteria for Rett syndrome, Typical (Neul et al,
             2010);

          -  Patient is participating in a clinical trial with another investigational drug

          -  Hypersensitivity to sarizotan or other 5-HT1a agonists;

          -  Current clinically significant (as determined by Investigator) cardiovascular,
             respiratory (e.g. severe asthma), gastrointestinal, renal, hepatic, hematologic or
             other medical disorders, in addition to those directly related to the patient's Rett
             syndrome;

          -  QTcF interval on the ECG is greater than 450 msec.

          -  Surgery planned during the study (except for insertion of gastrostomy tube);

          -  Severe diabetes mellitus or fatty acid oxidation disorder.

          -  Ophthalmologic history including any of the following conditions: albino patients,
             family history of hereditary retinal disease, retinitis pigmentosa, any active
             retinopathy or severe diabetic retinopathy.

          -  Females who are pregnant, breastfeeding, or of childbearing potential and not using a
             hormonal contraceptive.
      

Gender

All

Ages

4 Years - N/A

Accepts Healthy Volunteers

No

Contacts

Ravi Anand, MD, , 

Location Countries

Australia

Location Countries

Australia

Administrative Informations


NCT ID

NCT02790034

Organization ID

Sarizotan/001/II/2015


Responsible Party

Sponsor

Study Sponsor

Newron Pharmaceuticals SPA


Study Sponsor

Ravi Anand, MD, Study Director, Newron Pharmaceuticals


Verification Date

November 2021